Kroger commences Giving Hope a Hand campaign for breast cancer
CINCINNATI Kroger’s family of stores will showcase breast cancer survivors in its annual Giving Hope a Hand campaign to support breast cancer initiatives in communities across the country.
This year, 56 women share their stories of survival on marketing materials and custom packages of national and Kroger brand items, which will be sold exclusively in Kroger’s family of stores. Kroger’s campaign includes a storewide sales promotion of popular items, many of which will feature exclusive, specially marked pink packaging. This year, 1,800 items, including Kroger’s own products and popular items from such Kroger partners as Pepsi, Kellogg, Kraft, General Mills, Procter & Gamble and Kimberly Clark will be marked with special pink shelf tags to highlight their participation.
“All of us at Kroger applaud these terrific associates for choosing to share their personal stories of fighting breast cancer with our customers and associates,” said David Dillon, Kroger’s chairman and CEO. “We are pleased to have our great people featured in our annual campaign, as they inspire others to take care of themselves and each other.”
BI commences late-stage clinical trial for breast cancer treatment
INGELHEIM, Germany Boehringer Ingelheim has started a late-stage clinical trial of a drug for treating breast cancer, the German drug maker said Friday.
The phase 3 trial, dubbed the “LUX-Breast 1” trial, will evaluate the drug afatinib in patients with advanced breast cancer. The drug is a tablet that BI said was the first to inhibit two chemicals involved in tumor growth — the epidermal growth factor receptor, or EGFR, and the human epidermal receptor, also known as HER2.
“We have seen positive results in our proof-of-concept studies for afatinib in breast cancer, and are glad to advance the program into pivotal phase 3,” BI corporate SVP medicine Klaus Dugi said. “We are delighted to be able to initiate this important trial together with a range of leading investigators to assess the value of afatinib for women with advanced breast cancer.”
Emergent to develop anthrax vaccine on HHS’ behalf
WASHINGTON Emergent BioSolutions has landed a $51 million contract from the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority to develop a new anthrax vaccine.
In the first two years of the contract, Emergent will develop the final vaccine formulation and test its stability. HHS said it can extend the contract annually for up to three years to support scale-up and optimization for large-scale manufacturing, as well as additional animal studies needed to apply for Food and Drug Administration approval of the vaccine.
If the government extends the contract for all three years, the total five-year contract value could be $186.6 million.